We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Xechem International has announced that its subsidiary, Xechem Pharmaceuticals Nigeria, has received approval from Nigeria's drug regulatory authority, the National Agency for Food and Drug Administration and Control, for the marketing and sale of Nicosan for the prophylactic management of sickle cell disease.
Cardiome Pharma has announced amendments to its co-development agreement with Astellas Pharma related to the planned resubmission of the new drug application (NDA) for RSD1235 (iv), an investigational new drug for acute conversion of atrial fibrillation.
Roche has announced that the European Commission has approved MabThera (rituximab) as maintenance therapy for patients with relapsed or refractory follicular non-Hodgkin's lymphoma (NHL), the most common form of indolent NHL.
Dr Reddy's Laboratories, based in India, has introduced alfuzosin hydrochloride, indicated for treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
Watson Pharmaceuticals, Inc. and Andrx Corporation today announced that they have entered into an amendment to their March 12, 2006, definitive merger agreement pursuant to which, subject to certain conditions, the deadline to close the transaction has been extended from September 12, 2006, until November 13, 2006.
Alnylam Pharmaceuticals, a biopharmaceutical company developing novel therapeutics based on RNA interference, has amended its two existing RNAi collaboration agreements with Merck and consolidated the efforts into a single ongoing collaboration.
Teva Pharmaceutical Industries Ltd. of Jerusalem and Barr Pharmaceuticals Inc. of Woodcliff Lake, N.J., are among eight bidders for Pinewood Laboratories, a Tipperary, Ireland, generic-drug maker, the Sunday Times of London reported.
BioSante Pharmaceuticals, Inc. today announced that it has entered into definitive agreements with institutional and other accredited investors with respect to the private placement of 3,812,978 shares of its common stock at a purchase price of $2.00 per share, for gross proceeds of $7,625,956, before payment of placement agent commissions and offering expenses.
Adeza, a medical technology company located in Sunnyvale, California, announced that the US Food and Drug Administration (FDA) has granted the company's New Drug Application (NDA) for Gestiva Priority Review status.